NASDAQ: LPCN · Life Sciences · 10 alerts · CIK 1535955
Share price
$1.66Close, Nov 16
Market cap
$18.4M
Shares outstanding
11.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lipocine Inc. filings on SEC EDGAR ↗
Mahesh V. Patel, CEO, bought 50,000 shares of Lipocine Inc. at $1.58 to $1.60 a share (average $1.59) in 2 transactions, worth $79.5K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 211,495 (+13.4%).
Lipocine Inc. announced the dosing of the first participant in its BLOOM Phase 3 study of LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is expected to enroll approximately 120 participants and incorporates design improvements from a previous Phase 3 trial, with topline results expected in the second half of 2027.
Lipocine Inc. reported financial results for the third quarter of 2026, highlighting a net loss of $0.7 million and a cash position of $21.5 million as of September 30, 2026. The company also provided clinical updates, including the initiation of the Phase 3 BLOOM study for LPCN 1154 (BRLIZIO) in postpartum depression and the approval of TLANDO in Canada.
Lipocine Inc. reported total revenues of $2.6 million for the nine months ended September 30, 2026, driven by a $2.1 million license fee. Despite the revenue increase, the company incurred a net loss of $7.0 million due to higher operating expenses, though it maintains sufficient capital to fund operations through November 2027.
Lipocine Inc. has updated its corporate presentation for use in meetings with investors, analysts, and other stakeholders. The presentation was filed as Exhibit 99.1 to the 8-K and provides a strategic overview of the company's business and development pipeline.
Lipocine announced that Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males. The product is licensed to Verity Pharmaceuticals, which plans to launch and commercialize the oral therapeutic in the Canadian market by the end of 2026.
Lipocine Insider John W. Higuchi Buys $55K of Stock
John W. Higuchi bought 25,007 shares of Lipocine Inc. at $2.15 to $2.23 a share (average $2.20) in 2 transactions, worth $55K in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 241,365 (+7.1%).
Lipocine Insider John W. Higuchi Buys $27.1K of Stock
John W. Higuchi bought 12,561 shares of Lipocine Inc. at $2.16 a share, worth $27.1K in total on Sep 28, 2026. Shares held after the trade: 216,358 (+6.2%).